Converge Bio

Executive Summary

Converge Bio is an Israeli AI-driven drug discovery platform that leverages generative large language models (bio-LLMs) to design antibodies, optimize gene expression, and identify novel therapeutic targets. Founded in 2020, the company has raised $25 million and focuses on oncology and immunology, offering a cloud-based computational lab that provides private, royalty-free designs. Its approach accelerates early-stage discovery by using advanced AI to navigate the vast protein sequence space, potentially reducing the time and cost of preclinical development. The platform's ability to generate optimized antibody candidates and uncover new targets positions Converge Bio as a key player in the AI biotech landscape, with applications spanning protein therapeutics and beyond. Given the growing interest in AI-powered drug discovery and Converge Bio's strong foundation, the company is well-positioned to attract further investment and forge strategic partnerships. With a team of 50-200 employees based in Tel Aviv, Converge Bio combines deep biological expertise with cutting-edge machine learning. While still in the platform stage, its technology has the potential to disrupt traditional antibody development, and upcoming milestones—such as funding rounds or partnerships—will be critical for validating its approach and scaling its capabilities.

Upcoming Catalysts (preview)

• Q3 2026Series B Funding Round70% success
• Q4 2026Pharma Partnership for Antibody Design60% success
• Q2 2026Release of New Platform Capabilities or Validation Data80% success